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1. Introduction 
The Ca2+-ATPase is a membrane-bound protein that 
translocates Ca 2+ across the sarcoplasmic/endoplasmic 
reticulum membrane [1,2]. The protein has three distinct 
functional domains: the catalytic, the Ca 2+ transport do- 
main, and the stalk region, that connects the catalytic site 
to the region of the enzyme which translocates Ca 2+ 
[3-7]. The portion of the protein that contains the catalytic 
site faces the cytoplasmic side of the membrane, while the 
transmembrane h lices form a channel-like structure that 
allows Ca 2+ translocation across the membrane [4,6,7]. 
The catalytic and the Ca 2 ÷ sites are 50 A distant from one 
another. The coupling of these regions is achieved by a 
long range interaction traveling through the stalk region 
[6]. The Ca 2÷ pump is found in all animal cells so far 
studied, and in the same animal, different isoforms are 
expressed in different tissues [2]. The different Ca 2+- 
ATPase isoforms translocate calcium from the cytosol into 
the lumen of either the sarcoplasmic or endoplasmic reticu- 
lum of cells using the energy derived from the hydrolysis 
of ATP [1]. The catalytic cycle can be reversed and the 
same enzyme releases calcium from the intracellular store 
into the cytosol in a process coupled with the synthesis of 
ATP from ADP and Pi [8-10]. 
The present review focuses on the recent findings that 
the Ca 2 + pump can operate either as a pump (coupled) or 
as a transmembrane channel (uncoupled). Different drugs 
uncouple the Ca 2÷ pump. Some are physiological, such as 
arachidonic acid and heparin, and others are widely used in 
clinical practice, such as phenothiazines and anti-de- 
pressants. The response of the different uncoupling agents 
varies among the different Ca2+-ATPase isoforms. Thus, 
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when extrapolated to living systems, the same drug may 
have opposite effects in cytosolic Ca 2÷ homeostasis, de- 
pending on the tissue reached by the drug. 
2. The reaction sequence of  the Ca z + pump 
The catalytic ycle of the Ca 2 +-ATPase has been previ- 
ously described (Fig. 1 and Refs. [10,11]). During catalysis 
the enzyme cycles through two distinct conformations, E l 
and E 2 (originally E and * E, Ref. [12]). The key feature of 
this cycle is the mechanism by which energy is transduced. 
During the overall process of Ca 2 + transport, the chemical 
energy derived from the hydrolysis of ATP is converted 
into osmotic energy given by the Ca 2- gradient formed 
across the vesicle membrane. These two forms of energy 
are not directly interconverted in a single step. Different 
forms of energy are interconverted during the cycle and 
the energy needed for the translocation of Ca 2+ through 
the membrane becomes available to the enzyme before 
cleavage of the phosphoenzyme. When the transport be- 
gins, the energy derived from the binding of Ca 2+ and 
ATP to the enzyme is used for the formation of the 
phosphoenzyme and to change the conformation of the 
enzyme from E 1 to E 2 (reactions 1 to 4 in Fig. 1). During 
the conformational change (reaction 4), different events 
occur: (i) Ca 2+ is translocated through the membrane 
(work); (ii) there is a decrease of the water activity in the 
catalytic site of the enzyme (solvation energy) followed by 
a decrease of the energy of hydrolysis of the phosphoen- 
zyme (chemical energy); and (iii) the enzyme form E 2 has 
a lower affinity for Ca 2 + than the E l form, which permits 
the dissociation of Ca 2÷ into the reticulum lumen. The 
phosphoenzyme is only hydrolyzed after the dissociation 
of Ca 2+ (reactions 5 to 7) and the E 2 form is converted 
back into E~ in order to start a new cycle. Thus, binding, 
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conformational and solvation energy are interconverted 
during the process of transport. In the reversal of the Ca 2 ÷ 
pump, the energy derived from the Ca 2+ gradient is used 
for the synthesis of ATP from ADP and Pi and the 
different forms of energy are interconverted in the reverse 
order. Experimental evidence supporting this proposal has 
been obtained in different laboratories [12-32]. 
A second feature of the catalytic ycle is that the pump 
can work either in a coupled or uncoupled way (reactions 
8 to 11, Fig. 1). The classical view was that the ATPase 
could mediate a Ca 2÷ efflux in a process coupled to 
synthesis of ATP by the reversal of the reactions 1 to 7 
(Fig. 1). Recently, it has been shown that during Ca 2+ 
transport, part of the Ca 2+ accumulated by the vesicles 
leaks through the ATPase in a process not coupled to 
synthesis of ATP (reactions 9, 10 and 11, Fig. 1; and Refs. 
[33-37]). Measurements of exchange between the external 
and internal Ca 2÷ pools revealed that the coupling be- 
tween the Ca 2÷ exchange and ATP synthesis varies greatly 
depending on the enzyme phosphorylation level [38]. Con- 
ditions that favor phosphorylation of the enzyme by Pi, 
such as high P~ concentration, dimethyl sulfoxide 20% 
(v/v)  or the use of ITP as substrate decreases the Ca 2÷ 
efflux through the uncoupled route. Site-directed mutagen- 
esis of the region located between the transmembrane and 
stalk regions of the enzyme (Tyr763Gly) also promotes 
uncoupling of the pump [39]. 
3. Transmembrane channel of the Ca 2 +-ATPase 
The notion that the Ca 2+ pump can operate as a trans- 
membrane Ca 2÷ channel arose from experiments of unidi- 
rectional Ca 2÷ efflux in preparations enriched with vesi- 
cles derived from longitudinal tubules of the sarcoplasmic 
reticulum ('light vesicles'). This vesicle preparation does 
not contain 'ryanodine/caffeine-sensitive Ca 2+ channels' 
found in the terminal cistern of sarcoplasmic reticulum, 
nor does it exhibits the phenomenon of Ca2÷-induced 
Ca2÷-release [36,40,41]. 'Light' sarcoplasmic reticulum 
vesicles were preloaded with radioactive Ca 2 +, sedimented 
by centrifugation, and diluted into media containing EGTA. 
In the absence of substrates of the pump, Ca 2÷ leaks 
through the ATPase without concomitant synthesis of ATP 
[36,37]. Addition of natural igands of the ATPase, such as 
Ca 2÷, Mg 2+ and K ÷, block the Ca 2+ efflux through the 
pump [37,42]. The concentration of Ca 2+ needed for inhi- 
bition of Ca 2+ efflux is similar to that observed for 
binding of Ca 2÷ to the high-affinity sites of the enzyme, 
indicating that stabilization of Ca:E 1 form blocks the Ca 2÷ 
efflux. The binding of substrates uch as MgATP, ADP 
and Pi to the catalytic site also blocks efflux of Ca 2+ 
through the pump [37,43]. Phosphorylation of the ATPase 
by Pi decreases the Ca 2÷ efflux through reactions 9-11 
(Fig. 1) and increases the Ca 2÷ efflux coupled to the 
synthesis of ATP [37,44] because it favors the formation of 
Ca:E2-P forms and decreases the amount of Ca:E 2 forms 
needed for the release of Ca 2+ through the uncoupled 
route. Thapsigargin and cyclopiazonic acid, specific in- 
hibitors of the Ca 2÷ transport of SERCA isoforms [45,46], 
also block the uncoupled Ca 2÷ efflux through the Ca 2÷ 
pump [47,48]. In addition to the natural substrates of the 
ATPase, the uncoupled Ca 2÷ efflux is inhibited by the 
polyamines permine, spermidine and putrescine, which 
are found in different animal tissues, including skeletal 
muscle [49]. Ruthenium red, thought o be an inhibitor of 
Ca 2+ channels, also decreases the uncoupled Ca 2÷ efflux 
from light sarcoplasmic reticulum vesicles and competes 
with Ca 2+, Mg 2÷ and K + for their effects on the Ca 2÷- 
ATPase [42]. The concentration range in which polyamines 
block Ca 2+ efflux through the ATPase is the same as that 
observed in junctional vesicles, that contain the 'ryano- 
dine-sensitive Ca 2 ÷ channels' [40]. This provides evidence 
that binding of polyamines to the ATPase stabilize the 
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Fig. 1. The catalytic cycle of the sarcoplasmic reticulum Ca2+-ATPase. The enzyme form E I binds two Ca 2÷ with high affinity on the outer surface of the 
vesicles and can be phosphorylated by ATP but not by Pi (reaction 1). The phosphorylation f the ATPase is accomplished by transfer of phosphate from 
ATP to an aspartic residue located in the catalytic site of the enzyme (reactions 2 and 3). Phosphorylation f the enzyme by ATP is followed by a long 
range conformational change of the protein after which the Ca 2+ binding sites are reoriented, facing now the lumen of sarcoplasmic reticulum vesicles 
(reaction 4). Reorientation of the Ca 2+ sites is associated with a 103-fold decrease in the enzyme affinity for Ca 2+, favoring its dissociation into the 
vesicles lumen (reaction 5). Hydrolysis of the acyl phosphate (reactions 6 and 7) occurs after the Ca 2+ dissociation, generating the E 2 which is converted 
into E I in order to start a new catalytic cycle (reaction 8). The enzyme form E 2 binds calcium with low affinity in the inner surface of the vesicles and can 
be phosphorylated by Pi but not by ATP. Ca 2+ can be released from the vesicles to the external medium by the reversal of the Ca 2+ pump, in a process 
coupled to ATP synthesis (reactions 7 to 1 I). Alternatively, Ca 2+ leaks through the enzyme by an uncoupled route (reactions 9, 10 and 11). 
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ATPase channel in a closed state, in a manner similar to 
that observed with the Ca 2+ channel ocated in the termi- 
nal cistern of the sarcoplasmic reticulum. 
The transmembrane channel of the Ca2÷-ATPase may 
not be specific for Ca 2 +. Recently, it has been shown that 
the passive fluxes of K + and Na + through the sarco- 
plasmic reticulum membrane are blocked by thapsigargin, 
suggesting that the Ca2+-ATPase may also be involved in 
a passive monovalent cation exchange [50]. 
4. Opening of the Ca 2 +-ATPase channel 
Several drugs can uncouple the pump. They both inhibit 
the synthesis of ATP and induce an increase in the Ca 2+ 
efflux rate from the sarcoplasmic reticulum vesicles. The 
uncoupling drugs can be divided in two major groups: 
non-hydrophobic and hydrophobic drugs. Both groups of 
drugs seem to interact with the E 2 form of the enzyme and 
inhibit the phosphorylation of the enzyme by Pi, but are 
different in their potency. Arsenate and heparin are non- 
hydrophobic drugs that impair the synthesis of ATP and 
increase the Ca 2 + efflux to a rate similar to that measured 
during the reversal of the Ca 2+ pump [51-55]. In the E 2 
conformation, in which the enzyme binds Pi, the catalytic 
site has a hydrophobic haracter [19,23]. Thus, hydropho- 
bic molecules compete with Pi and inhibit the enzyme 
activity because they readily partition from the assay 
medium (hydrophylic) into the hydrophobic environment 
of the catalytic site (Fig. 2). A good correlation was found 
between the octanol/water partition coefficients of hy- 
drophobic molecules and their ability to inhibit the phos- 
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Fig. 3. Correlation between the hydrophobicity and inhibition of phospho- 
enzyme formation by local anesthetics. The values were obtained from 
octanol/water partition coefficients (F) and K i values for competition 
with both Pi (©) and Mg 2+ (0).  From Ref. [43]. 
phorylation of the ATPase by Pi (Fig. 3). A variety of 
hydrophobic drugs such as phenothiazines (Fig. 4 and Ref. 
[42]), local anesthetics [43], fatty acids [56] and ethanol 
[57] inhibit the synthesis of ATP and promote release of 
Ca 2+ through the pump at a rate much faster than that 
observed with the use of arsenate or heparin. These drugs 
increase the rate of Ca 2÷ efflux through the ATPase 
channel to levels that approaches those required for physi- 
ologic Ca 2÷ oscillations [42,43]. The effects of the hy- 
drophobic drugs on Ca 2÷ efflux are antagonized by lig- 
ands and substrates of the ATPase such as cations, nu- 
cleotides, polyamines, thapsigargin (Fig. 5). The Ca 2÷ 
concentration range required to completely block the 
drug-induced Ca 2+ efflux is narrow (1-10 IxM) and re- 
mains within physiological Ca 2÷ oscillations, providing an 
Jr !~ Pi +I ~-E Pi 
Fig. 2. Inhibition by hydrophobic drugs. The figure shows a schematic 
representation f the catalytic site of the sarcoplasmic reticulum Ca 2÷- 
ATPase. The first step for the synthesis of ATP is the phosphorylation by
Pi of an aspartic acid residue in the catalytic site. In the figure, I is a 
hydrophobic drug that may partition into the hydrophobic environment of
the catalytic site and impede the entry of the hydrophylic phosphate ion. 
For details, see Refs. [75,76]. 
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Fig. 4. Inhibition of Ca 2+ efflux by substrates and ligands (A) and 
enhancement by trifluoperazine (B). The reaction medium contained 50 
mM MOPS-Tris (pH 7.2), 2 mM EGTA and sarcoplasmic reticulum 
vesicles preloaded with 45Ca phosphate. The figure shows the Ca 2+ 
remaining in the vesicles after different incubation i tervals at 35°C. A: 
(0) 0.l mM Pi and 0.1 mM MgCI2; (O) 4 mM Pi and 4 mM MgCI2; 
(z~) 0.1 mM Pi, 0.1 mM MgC12 and 100 mM KCI; (A) EGTA was 
replaced by 0.2 mM CaCl 2. B: without addition (O), or plus 20 IxM 
(O), 40 IxM (A) and 100 p,M (•)  trifluoperazine. For details, see Ref. 
[47]. 
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Fig. 5. Concentration dependence of thapsigargin i hibition of Ca 2+ efflux activated by substrate and cofactor manipulations, or by chlorpromazine. 
Preloaded sarcoplasmic reticulum vesicles were diluted in 50 mM MOPS-Tris buffer (pH 7.0), 0.1 mM Pi, 0.1 mM MgCI2, 2 mM EGTA, with either no 
addition (0) or 0.2 mM chlorpromazine (©). For details, see Ref. [42]. 
interesting mechanism of blockage of Ca 2+ effiux after a 
critical high cytoplasmic Ca 2+ concentration is reached. 
5. Distinct Ca z +-ATPase isoforms are uncoupled differ- 
ently 
Three genes encode the Ca 2 +-ATPase isoforms. SERCA 
1 isoform is expressed in fast twitch skeletal muscle [3]. 
SERCA 2 gives rise to SERCA 2a and SERCA 2b iso- 
forms by alternative splicing. SERCA 2a is expressed in 
cardiac and slow skeletal muscle [58], while SERCA 2b is 
widely expressed in several non-muscle cells [59]. SERCA 
3 isoform is expressed mainly in platelets and lymphoid 
cells [60-62]. Recently, it has been shown that platelets 
express both SERCA 2b and SERCA 3 isoforms [61]. The 
meaning of isoform diversity is not clear at present. 
Heparin, a sulfated glycosaminoglycan found in the 
granules of mast cells, inhibits the Ca 2÷ ATPase isoforms 
of skeletal muscle and blood platelets [54]. Similar to as 
observed with arsenate, heparin uncouples the synthesis of 
ATP from Ca 2÷ efflux observed uring the reversal of the 
Ca 2÷ pump. In skeletal muscle, the effects of heparin are 
antagonized by K ÷, Na ÷, and to a lesser extent by Li ÷ 
[54,63]. However, the monovalent cations were not effec- 
tive as antagonist of heparin in platelet Ca2÷-ATPase [54]. 
Recently, it has been shown that for the platelet Ca 2+- 
ATPase, the stoichiometry between Ca 2+ released and 
ATP synthesized uring the reversal of the Ca 2+ pump is 
one and not two as in the muscle ATPase [55,64]. The 
Ca2+-ATPase isoforms of blood platelets have distinct 
substrate specificity and sensitivity to arsenate [55]. It has 
been proposed that the Ca 2 +-ATPase isoforms of platelets 
seem to be located in distinct functional Ca 2 + pools of the 
cell [55]. These results raise the possibility that the Ca 2÷- 
ATPase isoforms may play distinct roles in regulating the 
cytosolic Ca 2+ concentration in the cells. The Ca 2+- 
ATPase isoforms of platelets are also uncoupled by triflu- 
operazine but, different from sarcoplasmic reticulum, the 
effects of the drugs in blood platelet Ca 2 +-ATPase are not 
antagonized by thapsigargin or by the binding of Ca 2 + to 
the high-affinity sites of the enzyme [55]. Recently, it has 
been shown that brain microsomal Ca2+-ATPase (mostly 
SERCA 2b) has a distinct sensitivity to trifluoperazine. 
Trifluoperazine stimulates the Ca 2+ uptake in brain micro- 
somes by increasing the Ca 2+ pump efficiency, i.e., in- 
creasing the coupling ratio between Ca 2 ÷ transported/ATP 
hydrolyzed [63]. These results indicate that the coupling 
between the catalytic activity and the transmembrane chan- 
nel of the Ca2+-ATPase varies greatly depending on the 
isoform and tissue studied. 
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Fig. 6. Effect of pH on Ca 2+ efflux in the presence of external Ca 2+. 
Preloaded sarcoplasmic reticulum vesicles were diluted in 50 mM 
MOPS-Tris, 5 mM EGTA and increasing Ca 2+ concentrations to yield 
the desired free Ca 2+ at either pH 6.0 (O), 6.5 (z~) or 7.0 (0). For 
details, see Ref. [41]. 
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6. Does the ATPase channel play a role under physio- 
logical or pathological states? 
Ca 2+ plays a crucial role as a signaling agent in several 
physiological and pathological conditions [65]. In cellular 
ischemia and acidosis, in which intracellular pH falls to 
values as low as 6.1 [66-68],  Ca 2+ increases in the cytosol 
and promotes cellular injury [69,70]. We have investigated 
the effects of  pH on the coupling of the sarcoplasmic 
reticulum Ca 2+ pump [41]. Ca 2+ binds to the ATPase in 
pH dependent manner, and the affinity of  the enzyme to 
Ca 2+ decreases everal-fold when the pH of the medium is 
decreased from the physiologic value of 7.0 to acidic 
values in the range of 6.5 to 6.0 [17,71,72]. Although an 
increase of  the Ca 2+ concentration i  the medium inhibits 
the uncoupled Ca 2+ effiux at neutral pH, it has practically 
no effect at acid pH values (Fig. 6). In addition to reducing 
the apparent affinity to Ca 2+, acidification of  the efflux 
medium also discloses an effiux component insensitive to 
external Ca 2+. The effects of  Mg 2+ and K + on the Ca 2+ 
effiux observed at neutral pH are also abolished at acidic 
pH values. The potency of  hydrophobic uncoupling drugs 
in enhancing the efflux of  Ca 2+ decreases at acid pH, but 
the effect of  the drugs are no longer blocked by cations. 
Thus, at acid pH, the ATPase channel remains open re- 
gardless the concentration of  cations in the medium. This 
pH-dependent effiux pathway may play a role in condi- 
tions of  intracellular acidosis, as for instance in muscle 
ischemia. Activation of  the Ca 2+ effiux through the AT- 
Pase is also observed with fatty acids naturally found in 
muscle cells [56]. The intracellular concentration of fatty 
acids (e.g., arachidonic acid) increases everal-fold uring 
cellular ischemia, reaching values as high as 0 .1-0 .4  mM 
[73,74]. The effect of  low concentrations of arachidonic 
acid (8 -16  IxM) on Ca 2+ efflux is blocked by the same 
agents that block the effects of  phenothiazines and local 
anesthetics. Thus, fatty acids are physiological candidates 
to promote Ca ~+ release through the pump. 
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